Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-29
1997-06-10
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514912, A61K 3142
Patent
active
056376049
ABSTRACT:
A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a muscarinic pharmacological antagonist relatively selective for blocking the cholinergic receptors in cells of the brain, neural tissue and/or neural ganglia but less selective for blocking the cholinergic receptors of the cells of smooth muscles at the front of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is pirenzepine. Other suitable antagonists are telenzepine and o-methoxy-sila-hexocyclium.
REFERENCES:
patent: 4865599 (1989-09-01), Chiou
patent: 5055302 (1991-10-01), Laties et al.
patent: 5122522 (1992-06-01), Laties et al.
patent: 5284843 (1994-02-01), Stone et al.
patent: 5356892 (1994-10-01), Laties et al.
patent: 5360801 (1994-11-01), Laties et al.
patent: 5385939 (1995-01-01), Laties et al.
Meythaler et al. The Myopic and Miotic Effect of Pilocarpin and Glaucostat Albrecht v. Graefes Arch. Klin. Exp. Ophthal. 1971 181:234-245 published by.
Birdsall et al. Pirenzepine--a Ligant With Original Binding Properties to Muscarinic Receptors Scand. J. Gastro 1980 1-4.
Bedrossian R. The Effect of Atropine on Myopia Ophthalmology 1979 86:713-717.
Buckley et al. Antagonist Binding Properties of Five Cloned Muscarinic Receoptors Expressed in CHO K1 Cells Am. Soc. Pharm. Exp. Ther. 35:469-476 1989.
Curtin The Myopias--Basic Science and Chemical Management Harper & Row 1985 220-225.
Goss D.A. Attempts to Reduce the Rate of Increase of Myopia in Young People--A Critical Literature Review Am. Jour. Ophth. & Physc. Optics 1982 59:828-841.
Hagan et al. The Relative Potencies of Cholinominetics and Muscarinic Antagonists on the Rat Iris in Vivo: Effects of pH on Potency of Pirenzepine and Telenzepine NS Arch Pharmacology 1988 338:476-483.
Hammer et al. Selective Muscarinic Receptor Antagonists TIPS Jun. 1982.
Heathcote et al. Pirenzepine Selectively Inhibits Gastric Acid Secretion: a Comparative Pharmacological Study Between Pirenzepine and Seven Antiacetylcholine Drugs Scand. J. Gastro 1980 15-23.
Jaup et al. Comparison of the Action of Pirenzepine and L-Hyoscyamine on Gastric Acid Secretion and Other Muscarinic Effects Scand. J. Gastro 1980 89-94.
Jaup et al. Cerebrospinal Fluid Concentration of Pirenzepine After Therapeutic Dosage Scand. J. Gastro. 1980 35-37.
Lambrecht et al. o-Methoyoxy-sila-hexocyclium: a New Quaternary M.sub.1 -Selective Muscarinic Antagonist Euro. Journ. Pharm. 1988 151:155-156.
Meriney et al. Cholinergic Innervation of the Smooth Muscle Cells in the Ceroid Coat of the Chick Eye and its Development J. Neuro. Sci. 1987 7:3827-3839.
Perr et al. Cyclic Nucleotides Regulate Collagen Production by Human Intestinal Smooth Muscle Cells Gastroenterology 1989 96:1521-1528.
Raviola et al. An Animal Model of Myopia N.E. Jour. Med. 1985 313:1162-1163.
Rubin et al. Myopia--A Treatable "Disease"? Survey of Ophthalmology 1976 21:65-69.
Scandinavian Journal of Gastroenterology Papers published ion 8 on Advances in Basic and Clinical Pharmacology of Pirenzepine Jun. 1980.
Schudt C. The Affinity, Selectivity, and Biological Activity of Telenzepine Enantiomers Euro. Jour. Pharm. 1989 165:87-96.
Stone et al. Altered Retinal Amine Neurotransmitters in Form-Deprivation Myopia Soc. Neurosci. 1987 13:240.
Lin et al. Altered Dopamine Metabolism and Form-Derivation Myopia Invest. Ophth. Vis. Sci. 1988 29:33.
Taylor P. Pharmaceutical Basis of Therapeutics 1985 7th Ed. MacMillan Publ. Cholinergic Agonists Ch. 5, 100-108.
Mosinger et al. Gaba-like Immunoreactivity in the Vertebrate Retina: A Species Comparison Exp. Eye Res. 1986 42:631-644.
Fiszer DePlazas et al. Light and Dark Adaptation Infulences Gaba Receptor Sites in the Chick Retina Neurochemical Res. 1986 11:973-981.
Ikeda et al. Actions of baclofen and phaclofen upon ON-and OFF-ganglion cells in the cat retina European J. Pharm. 1990 190:1.
Iuvone et al. Dopamine mediates the light-evoked suppression of serotonin N-acetyltransferase activity in retina Brain Research 1987 418:314-324.
The Merck Index, Tenth Edition, Martha Windholz, ed., 1983 772-773.
Society of Neuroscience Meeting, Abstract, Nov. 16-21, 1987 71.14:240.
Hoffmeister et al. Psychotropic Agents Part I Antipsychotics and Antidepressants, Zeelen F. Chemistry Structure and Activity Springer Verlag, New York 1980.
Stone et al. Muscarinic Antagonist Effects on Experimental Chick Myopia Exp. Eye Res. 1991 52:755-758.
Carter et al. Treating Blurred Vision Associated with Antipsychotic Medication Amer. Jour. Phychiatry 1977 134:941.
Francois et al. Ultrasonographic Study of the Effect of Different Miotics on the Eye components Ophthalmologica, Basel 1977 175:328-338.
The Merck Index Eleventh Edition Ed., Windholz 1989 80 and 780.
Laties Alan M.
Stone Richard A.
Fay Zohreh
The Trustees of the University of Pennsylvania
LandOfFree
Treatment and control of ocular development does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and control of ocular development, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and control of ocular development will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764885